204 related articles for article (PubMed ID: 18552083)
1. Olig2 and CD99 are useful negative markers for the diagnosis of brain tumors.
Ishizawa K; Komori T; Shimada S; Hirose T
Clin Neuropathol; 2008; 27(3):118-28. PubMed ID: 18552083
[TBL] [Abstract][Full Text] [Related]
2. SOX10 and Olig2 as negative markers for the diagnosis of ependymomas: An immunohistochemical study of 98 glial tumors.
Švajdler M; Rychlý B; Mezencev R; Fröhlichová L; Bednárová A; Pataky F; Daum O
Histol Histopathol; 2016 Jan; 31(1):95-102. PubMed ID: 26287936
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical expression of Olig2, CD99, and EMA to differentiate oligodendroglial-like neoplasms.
Kurdi M; Eberhart C
Folia Neuropathol; 2021; 59(3):284-290. PubMed ID: 34628794
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical study of CD99 and EMA expression in ependymomas.
Mahfouz S; Aziz AA; Gabal SM; el-Sheikh S
Medscape J Med; 2008 Feb; 10(2):41. PubMed ID: 18382710
[TBL] [Abstract][Full Text] [Related]
5. OLIG2 is a useful immunohistochemical marker in differential diagnosis of clear cell primary CNS neoplasms.
Preusser M; Budka H; Rössler K; Hainfellner JA
Histopathology; 2007 Feb; 50(3):365-70. PubMed ID: 17257132
[TBL] [Abstract][Full Text] [Related]
6. Nogo-A: a useful marker for the diagnosis of oligodendroglioma and for identifying 1p19q codeletion.
Marucci G; Di Oto E; Farnedi A; Panzacchi R; Ligorio C; Foschini MP
Hum Pathol; 2012 Mar; 43(3):374-80. PubMed ID: 21835431
[TBL] [Abstract][Full Text] [Related]
7. Sensitivity and specificity of epithelial membrane antigen staining patterns in ependymomas.
Hasselblatt M; Paulus W
Acta Neuropathol; 2003 Oct; 106(4):385-8. PubMed ID: 12898159
[TBL] [Abstract][Full Text] [Related]
8. The oligodendroglial lineage marker OLIG2 is universally expressed in diffuse gliomas.
Ligon KL; Alberta JA; Kho AT; Weiss J; Kwaan MR; Nutt CL; Louis DN; Stiles CD; Rowitch DH
J Neuropathol Exp Neurol; 2004 May; 63(5):499-509. PubMed ID: 15198128
[TBL] [Abstract][Full Text] [Related]
9. Immunolocalization of the oligodendrocyte transcription factor 1 (Olig1) in brain tumors.
Azzarelli B; Miravalle L; Vidal R
J Neuropathol Exp Neurol; 2004 Feb; 63(2):170-9. PubMed ID: 14989603
[TBL] [Abstract][Full Text] [Related]
10. Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology.
Capper D; Reuss D; Schittenhelm J; Hartmann C; Bremer J; Sahm F; Harter PN; Jeibmann A; von Deimling A
Acta Neuropathol; 2011 Feb; 121(2):241-52. PubMed ID: 21069360
[TBL] [Abstract][Full Text] [Related]
11. Diversity of glial cell components in pilocytic astrocytoma.
Tanaka Y; Sasaki A; Ishiuchi S; Nakazato Y
Neuropathology; 2008 Aug; 28(4):399-407. PubMed ID: 18312545
[TBL] [Abstract][Full Text] [Related]
12. CD99 immunoreactivity in ependymoma.
Choi YL; Chi JG; Suh YL
Appl Immunohistochem Mol Morphol; 2001 Jun; 9(2):125-9. PubMed ID: 11396629
[TBL] [Abstract][Full Text] [Related]
13. Nogo-a expression in glial CNS tumors: a tool to differentiate between oligodendrogliomas and other gliomas?
Kuhlmann T; Gutenberg A; Schulten HJ; Paulus W; Rohde V; Bruck W
Am J Surg Pathol; 2008 Oct; 32(10):1444-53. PubMed ID: 18685489
[TBL] [Abstract][Full Text] [Related]
14. CD99 is upregulated in placenta and astrocytomas with a differential subcellular distribution according to the malignancy stage.
Úrias U; Marie SK; Uno M; da Silva R; Evagelinellis MM; Caballero OL; Stevenson BJ; Silva WA; Simpson AJ; Oba-Shinjo SM
J Neurooncol; 2014 Aug; 119(1):59-70. PubMed ID: 24797829
[TBL] [Abstract][Full Text] [Related]
15. OLIG2 as a specific marker of oligodendroglial tumour cells.
Marie Y; Sanson M; Mokhtari K; Leuraud P; Kujas M; Delattre JY; Poirier J; Zalc B; Hoang-Xuan K
Lancet; 2001 Jul; 358(9278):298-300. PubMed ID: 11498220
[TBL] [Abstract][Full Text] [Related]
16. Shared oligodendrocyte lineage gene expression in gliomas and oligodendrocyte progenitor cells.
Bouvier C; Bartoli C; Aguirre-Cruz L; Virard I; Colin C; Fernandez C; Gouvernet J; Figarella-Branger D
J Neurosurg; 2003 Aug; 99(2):344-50. PubMed ID: 12924709
[TBL] [Abstract][Full Text] [Related]
17. OLIG2 is differentially expressed in pediatric astrocytic and in ependymal neoplasms.
Otero JJ; Rowitch D; Vandenberg S
J Neurooncol; 2011 Sep; 104(2):423-38. PubMed ID: 21193945
[TBL] [Abstract][Full Text] [Related]
18. Expression of the oligodendroglial lineage-associated markers Olig1 and Olig2 in different types of human gliomas.
Ohnishi A; Sawa H; Tsuda M; Sawamura Y; Itoh T; Iwasaki Y; Nagashima K
J Neuropathol Exp Neurol; 2003 Oct; 62(10):1052-9. PubMed ID: 14575240
[TBL] [Abstract][Full Text] [Related]
19. Utility of combining OLIG2 and SOX10 IHC expression in CNS tumours: promising biomarkers for subtyping paediatric- and adult-type gliomas.
Aboubakr O; Métais A; Maillard J; Hasty L; Brigot E; Berthaud C; Lacombe J; Pucelle N; Raynal J; Appay R; Varlet P; Tauziède-Espariat A
Histopathology; 2024 Apr; 84(5):893-899. PubMed ID: 38253970
[TBL] [Abstract][Full Text] [Related]
20. Expression of oligodendrocyte lineage genes in oligodendroglial and astrocytic gliomas.
Riemenschneider MJ; Koy TH; Reifenberger G
Acta Neuropathol; 2004 Mar; 107(3):277-82. PubMed ID: 14730454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]